Connect with us

Emerging Markets

Pervasip Corp (OTCMKTS: PVSP) Heating Up as Artizen Subsidiary Reports Record Sales Growth & Rapid Build Out of its New Tacoma Cultivation Facility

Published

on

Pervasip Corp (OTCMKTS: PVSP) has been on the move northbound in recent weeks on a surge of trading volume and renewed interest from investors. PVSP has runner in its blood and saw a big move this time last year. The stock also has an established and significant shareholder base that will be back into PVSP heavily now that a clear upward momentum has been established. Currently PVSP trades just over 52 week lows and has a very significant gap to fill from where it was trading in April 2021. A big announcement is on the horizon; on the Company’s twitter account they posted: “Hello $PVSP shareholders: We are pleased to announce we are in the final phase of closing a strategic partnership that management believes will add an enormous amount of revenue to our bottom line. We look forward to announcing the details soon. Stay tuned!” 

There are a lot of exciting things happening at PVSP; the Company’s 5% stake in KRTL Biotech seems to be paying off but it’s the Artizen acquisition that is bringing significant revenues to PVSP, revenues that put Pervasip above 99% of stocks on the OTCQB. Artizen is one of Washington’s original cannabis brands and is recognized as one of the most reputable leading consumer brands in the state. Earnings. Recognized as the 9th bestselling independent cannabis flower brand by MJ Business Magazine, Artizen further strengthened its market position by winning this year’s Dockside Cannabis Cup with its Dutchberry strain. Artizen subsidiary ZAM (Zen Asset Management) currently manages four licensed cultivation facilities and one licensed processing facility in Washington state. ZAM is also building out a next generation 24,000 square ft of cultivation and 9,000 square ft of processing capacity. PVSP has graduated to the revenue big leagues on the OTCQB reporting $17.1 million in revenue and about $530,000 in net income in fiscal 2021. For 2022 management is predicting big things; Artizen revenues are expected to incrase substantially by as much as 50% according to some. The Company is also expecting around $6 million in annual revenues from the Tacoma facility once its completed and another $5 million in annual revenues from the partnership with Full Spectrum Advisors. 

Pervasip Corp (OTCMKTS: PVSP) is a developer of companies and technologies in high value emerging markets, owns Artizen Corporation and its subsidiary, Zen Asset Management LLC, a diversified asset management company founded to acquire, develop, and support companies and technologies in the cannabis industry. ZAM’s existing clients operate four licensed cannabis cultivation and one processing facility in Washington. Most of the biomass produced by these independent cultivators has been sold historically under the Artizen™ brand, including all-time top selling products in flower in Washington state. Pervasip additionally owns 5% of KRTL Biotech, Inc., a developer of biotechnologies with a focus on pharmaceutical grade resources and technologies as well as disciplines in the CBD, Psilocybin and certain psychedelics arena. The company’s scientists are leaders in cancer and neurology research, with over 80 years of experience in the research industry. KRTL Biotech Inc. has obtained the coveted approval of Korea’s Ministry of Food and Drug Safety (MFDS), formerly known as the Korea Food & Drug Administration (KFDA).  The company has partnered with a multitude of universities and biotech companies to facilitate this venture. 

Last year PVSP acquired Artizen Asset Management LLC (“AAM”) the parent of Zen Asset Management LLC (“ZAM”), a diversified asset management company that was founded to acquire, develop, and support companies and technologies in the cannabis industry. ZAM manages four licensed cultivation facilities and one licensed processing facility in Washington state under a series of management, leasing, licensing and other long-term agreements.  

To Find out the inside Scoop on PVSP Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

PVSP

As one of Washington’s original cannabis brands, Artizen-branded products are the all-time fourth best-selling in Washington across all product categories, and the all-time third in flower, with five of the all-time top ten selling products in flower. Eighths of Artizen’s flagship Dutchberry™ flower are the all-time top selling flower product in Washington. Artizen’s commitment to quality and consistency has built a substantial following, fueling more than $69 million in wholesale sales to a distribution network with more than 200 retailers, corresponding to more than $200 million in retail value since inception in 2015. Go here for a full list of Artizen’s flower. 

The Artizen brand is recognized as one of the most reputable leading consumer brands in Washington state, with tremendous consumer and retailer recognition. Management believes ZAM’s results in Washington are scalable with the right investment and management. Sales of Artizen-branded products have grown by more than 25% during the three years ended December 31, 2020, to more than $17 million in 2020. While that growth was historically driven by the continuing strong demand for Artizen-branded products, that demand significantly exceeds supplies. Additional growth is constrained by the availability of financing to invest in ZAM’s infrastructure and help its customers to increase utilization, sales, and earnings. Just last week ArtizenTM was announced as the winner of the esteemed Washington State 2022 Dockside Cannabis Cup. Recognized as the 9th bestselling independent cannabis flower brand by MJ Business Magazine, Artizen further strengthened its market position by winning this year’s Dockside Cannabis Cup with its Dutchberry strain. 

Currently ZAM (Zen Asset Management) is building out a next generation cultivation facility in Tacoma, Washington consisting of 24,000 square feet of cultivation and 9,000 square feet of processing capacity, which ZAM will manage for three new ZAM customers. The new cultivation facility is projected to produce 500 pounds per month of high-quality cannabis flower and is scheduled for completion and launch by end of 2022. Pervasip management estimates the additional output to be initially valued at about $6 million in annualized revenues, with pre-tax operating income margins exceeding 10%. 

In March Pervasip reported $17.1 million in revenue and about $530,000 in net income attributable to Pervasip’s shareholders for the year ended November 30, 2021 coming from its Artizen subsidiary. Wholesale sales increased by 330% for the year ended November 30, 2021, as compared to the year ended November 30, 2020, putting the Company on track to increase total sales to more than $30 million per year after construction of the Tacoma cultivation facility is completed. Pervasip Finanancial results will be further boosted by the Company’s strategic partnership with Full Spectrum Advisors (“FSA”), a cannabis cultivation group that has designed and operated over 7 million square feet of indoor canopy along with pioneering cutting-edge crop steering techniques. This partnership is expected to boost PVSP revenues by an additional $5 million annually over the next 24 months. 

After recently announcing record Q1 financial results, CEO German Burtscher stated: “Our team has executed the first half of our restructuring plans flawlessly over the past few months. Improved gross margins, achieving positive EBITDA and quarter over quarter revenue growth even in the traditionally slowest quarter in our industry and compared to a pandemic high Q1 2021 is a testament to our strength, the direction of the Company and the power of the Artizen brand, “Our infrastructure is on track to achieve per square foot target objectives for harvest yields by Q4 this year, which will yield a 50% increase in output from all gardens. Together with the buildout of our new state of the art cultivation facility, this will continue to improve the company’s revenue and profitability.” 

We have a Monster Pick Coming. Subscribe Right Now!

PVSP is an exciting story developing in small caps; the Company’s Artizen acquisition continues to pay off in spades achieving $17.1 million in revenue and about $530,000 in net income in fiscal 2021. For 2022 management is predicting big things; Artizen revenues are expected to incraese substantially by as much as 50% according to some sources; added to that will be an addition $10 million in new revenues coming from the new Tacome facility and the partnership with Full Spectrum Advisors. Management is excited about the Company’s pospects recently stating: “The Company started 2022 in a strong position according to management; We ended 2021 with numerous accomplishments, healthy financials, an amazing lineup of new opportunities, various strategic initiatives, and a companywide restructuring that we concluded over the past 3 months, after completing our acquisitions of Artizen Corporation and its subsidiary, Zen Asset Management LLC in September 2021. We have an amazing foundation to grow from in 2022, including close to $17 million in annual revenues, positive EBIDTA, one of the most established cannabis management companies in Washington state, and the intellectual property behind one of the top 10 national cannabis brands.” We will be updating on PVSP when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with PVSP.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in PVSP either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma

Cosmos Holdings Inc (NASDAQ: COSM) Huge Short Position Panicks as COSM Rockets Up the Charts

Published

on

Cosmos Holdings Inc (NASDAQ: COSM) is rocketing up the charts northbound since reversing off $0.0675 lows earlier this month where we first gave the heads up on COSM at around a dime in our article here. Since than COSM has rocketed northbound recently surpassing $0.60 per share with speculators pointing at $1 as the next stop. In our previous article on COSM on November 13 when COSM was $0.10 we stated: “COSM was trading well over $3 at the beginning of this year but has been heavily shorted since than with current estimates of well over 5 million shares sold short and almost the entire public float sold short. 

While COSM has been heavily shorted into oblivion, the Company is actually doing quite well recently reporting revenues for the 3 months ended September 30 were $12 million. The Company is successfully developing their business recently closing a deal with Iberica, a European Airline, for in flight distribution of their products. The CEO has bought millions of shares at current levels and COSM is beginning to go viral on social media trending on the sub reddit Short Squeeze, Number #1 on Stocktwits and multiple videos being made on YouTube about a massive short squeeze taking place in small caps. 

COSM Friday December 2, 4PM Close Update: COSM had a wild trading day on Friday dropping to $0.42 in the morning before rocketing up to $0.61 highs. This was followed by another drop to the $0.47 range before COSM rocketed up in late afternoon trading, closing at $0.53 on 205 million shares traded. COSM was up 33% on the day on around $110 million in dollar volume. COSM is setup for an enormous week ahead, looking to overtake the $0.845 from Monday and embark on a blue-sky breakout with $1 as the first stop. We gave the heads up on COSM when the stock was below $0.10 per share at the beginning of November. We will be updating on COSM as soon as anything new happens so make sure you are subscribed to Microcapdaily by entering your email in the box below.  

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

No alternative text description for this imageCosmos Holdings Inc (NASDAQ: COSM) is a global healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation.” Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. 

The Number #2 post on the subreddit ShortSqueeze currently is titled: COSM about to test resistance. A pump through $0.66 and lift off to over $1.00 is possible now. 

In another post on COSM in the subreddit ShortSqueeze rubio2430 states: “$COSM you cant make this stuff up. this baby is ready for space. the shorts are burying themselves on the daily. constant pr’s, growing fundamentals, no plans on dilutions, dual listing on upstream soon—the list goes on! 

nimble_broccoli replied: Why this is a good play: 

1.) Extremely tiny Marketcap 2.) CEO buying 15’000’000 shares 3.) Good fundamentals, unlike other plays, they actually sell products valued around 10x the valuation. Q1/22 was profitable. 4.) Getting momentum on social media (Reddit Twitter, YT) 

Next catalysts: -Info that they will not be delisted from NASDAQ -Degen and Retail FOMO kicking in -Shorts starting to cover their asses 

In addition, consider this: The stock was somewhere between USD 2 and USD 12 the past ~8 years. Most Hodlers bought back then, do you think they will sell now? Do your own thinking but if one of my stocks dropped 80+ % i d not sell, i d just hope for a miracle or ride it out. Thus, not many regular buy&hold holders of the stock are expected to sell. 

Cosmos operates in the business of full-line pharmaceutical wholesale distribution and serves approximately 1,500 independent retail pharmacies and 40 pharmaceutical wholesalers in Greece region by providing brand-name and generic pharmaceuticals, over-the-counter medicines, vitamins and nutraceuticals. Cosmos invests in technology to enhance safety, distribution and warehousing efficiency and reliability. Specifically, the Company operates a fully automated warehouse system with three robotic systems, two ROWA™ types and one A-frame type, that ensure 0% error selection rate, accelerate order fulfillment, and yield higher cost-efficiency in our distribution center. Cosmos has 3 operating subsidiaries including:

SkyPharm
Sky Pharm SA is headquartered in Thessaloniki, Greece. Sky Pharm trades the excess amounts of about 500 medicines that can be exported within the EU countries. We buy from Greek wholesale pharmaceutical companies and multinational pharmaceutical manufacturers, and export to European markets where demand and prices are substantially higher.
.
DHN
Decahedron Ltd. is a pharmaceutical wholesaler incorporated in the UK in August 2011. It is audited by the MHRA under European GDP (Good Distribution Practices). They are also a full member of the EAEPC and have been audited by TÜV on their behalf.
.
Cosmofarm
Founded in 1994, Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. The company is approved and authorized by the National Organization for Medicines under Good Distribution Practices to distribute a comprehensive range of pharmaceutical products. Cosmofarm’s core activity is sourcing, procuring, and distributing branded.
.
To Find out the inside Scoop on COSM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

COSM

Image

COSM business is strong and Q3 highlights include closing a $7.5M capital raise via public offering and signing an exclusive agreement to market and distribute Nickelodeon’s SpongeBob and PAW Patrol kids’ vitamins in Greece and Cyprus, aiming to reach out 11,000 pharmacies and 120 wholesalers in Greece and 780 pharmacies in Cyprus. They also executed a letter of intent for a strategic co-venture agreement with Smart for Life (SMLF) to cross market products and services in their reciprocal markets. COSM also entered into an LOI to acquire ZipDoctor Inc., and entered into an agreement with Virax Biolabs (VRAX), to become the distributor of Monkeypox Virus Real-Time PCR Detection Kits, having the exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute the test kits across Europe on a non-exclusive basis. SkyPharm officially launched its first Sky Premium Life products on Amazon in the United States. Cosmos targets having all 85 SKUs listed on Amazon by year end. COSM entered into an LOI to acquire Pharmaceutical Laboratories CANA S.A., and another LOI to acquire LIFE NLB, Ltd.’s product portfolio, including Bone-Vio® and Bone-X, related to bone health targeting the human gastrointestinal microbiome. 

Last week COSM announced its Sky Premium Life luxury food supplement brand will be sold on Ronda, the official inflight magazine of the airline company Iberia of BRITISH AIRWAYS group. Ronda is available free of charge to the over 10 million passengers who fly Iberian Airlines annually. Iberia Airlines, majority owned by British Airways, has a fleet of 147 aircrafts and engages in over 600 daily flights. 

https://twitter.com/nxtplse/status/1597365583934545920

For More on COSM Subscribe Right Now!

Currently trading at a $36 million market valuation COSM os is 92,008,281 the Company recently reported Q3 Revenues of $12 million down a bit from the same time last year due to a high variation in FX differences between EUR and GBP to USD. COSM was trading over $4 this time last year however OS has increased substantially since then.  COSM is an exciting opportunity in small caps; the stock was shorted into oblivion and currently there are minimum 5.8 million shares short and was way oversold to pennies and it looked as if it would definitely get delisted by the Nasdaq however, led by able CEO Grigorios Siokas, Cosmos is fighting back. Mr. Siokas continues to buy more COSM at current price levels, putting his money where his mouth is as COSM rockets towards $1 which is now just a day and half away if the stock continues up at the same trend.  We will be updating on COSM when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in COSM either long or short and we have not been compensated for this article.

Continue Reading

BioPharma

Cosmos Holdings Inc (NASDAQ: COSM) Heating Up as Co Looks to Take on Massive 5 million Share Short Position

Published

on

Cosmos Holdings Inc (NASDAQ: COSM) is making a rapid move up the charts since recent reversing off $0.0675 lows. The stock was trading well over $3 at the beginning of this year but has been heavily shorted since than with current estimates of well over 5 million shares sold short and almost the entire public float sold short. COSM is quickly emerging as the latest short squeeze at the top of speculators watch lists and is currently trending on stocktwits and the sub reddit ShortSqueeze on Reddit. 

The Company is fighting back against the shorts and planning a lawsuit and CEO Grigorios Siokas recently put his money where his mouth is when he bought 12,500,000 shares of the stock at $0.12 average for about $1.5 million. While in danger of being delisted from the Nasdaq if they don’t get the stock price back over $1 by the end of November the Company is doing well recently reporting its first ever net income on $13,208,504 in revenues for the 3 months ended June 30, 2022. Cosmos is also acquiring ZipDoctor Inc. from American International Holdings Corp (AMIH) 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Cosmos Holdings Inc (NASDAQ: COSM) is an international healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. On August 2, 2022, the Company filed a Fictitious Firm Name Certificate in Nevada to do business under the name Cosmos Health, Inc. and will seek shareholder approval at its annual shareholders meeting scheduled for December 2, 2022 to amend its Articles of Incorporation for the name change. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation.” Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and over-the-counter (“OTC”) medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors.  

Cosmos operates in the business of full-line pharmaceutical wholesale distribution and serves approximately 1,500 independent retail pharmacies and 40 pharmaceutical wholesalers in Greece region by providing brand-name and generic pharmaceuticals, over-the-counter medicines, vitamins and nutraceuticals. Cosmos invests in technology to enhance safety, distribution and warehousing efficiency and reliability. Specifically, the Company operates a fully automated warehouse system with three robotic systems, two ROWA™ types and one A-frame type, that ensure 0% error selection rate, accelerate order fulfillment, and yield higher cost-efficiency in our distribution center. Cosmos has 3 operating subsidiaries including:

SkyPharm
Sky Pharm SA is headquartered in Thessaloniki, Greece. Sky Pharm trades the excess amounts of about 500 medicines that can be exported within the EU countries. We buy from Greek wholesale pharmaceutical companies and multinational pharmaceutical manufacturers, and export to European markets where demand and prices are substantially higher. The …
DHN
Decahedron Ltd. is a pharmaceutical wholesaler incorporated in the UK in August 2011. It is audited by the MHRA under European GDP (Good Distribution Practices). They are also a full member of the EAEPC and have been audited by TÜV on their behalf. They import and export branded, generic and …
Cosmofarm
Founded in 1994, Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. The company is approved and authorized by the National Organization for Medicines under Good Distribution Practices to distribute a comprehensive range of pharmaceutical products. Cosmofarm’s core activity is sourcing, procuring, and distributing branded

https://twitter.com/ChairmanOtc/status/1590877348752420866

To Find out the inside Scoop on COSM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

COSM

ImageOn August 22 Cosmos provided a business update and reported financial results for the second quarter and six months ended June 30, 2022. Revenues were $13,208,504 for the 3 months ended June 30, 2022 compared to $14.8 million for the same period last year. 

Greg Siokas, Chief Executive Officer of Cosmos Health, stated, “We increased our profitability for the first half of 2022 due to the increase of gross profit margin to 14.2% from 11.5% for the respective period of 2021. This increase is attributed mainly to the organic growth of our proprietary nutraceutical brand, Sky Premium Life® (“SPL”). We achieved positive income from operations of $0.2 million for the first half of 2022 compared to a loss of $3.1 million in the same period last year and positive EBITDA of $0.8 million for the first half of 2022 compared to a loss of $2.8 million for the same period last year. Gross profit increased by 23.0% to $3.7 million for the six months ended June 30, 2022. We continue to carefully manage expenses and reduced operating expenses by nearly 43.7% and 41.9% for the three and six months ended June 30, 2022, respectively. During the quarter, we launched a new premium line of nutritional supplements, Mediterranation. The Mediterranation line uses organic herbs and plant extracts such as crataegus, hibiscus, dittany of Crete, oregano, mastic and kritamos, found in specific regions in Greece and the Mediterranean. These unique formulations contain a proprietary blend of vitamins and minerals and are made with the highest quality raw materials. There is high demand among consumers for supplements that utilize high quality Mediterranean ingredients, such as polyphenols, which possess antioxidant and anti-inflammatory properties. We expect the launch of the Mediterranation line will further enhance our growth strategy and we look forward to expanding the product line into new global markets through our growing distribution channels. We also launched our SPL products on Amazon Singapore and are in the process of launching on Amazon United States and Amazon Canada in the third quarter of 2022. These new markets provide an untapped growth opportunities and new audiences for our proprietary SPL brand. Our goal is to grow our portfolio of branded nutraceuticals and reach up to 150 SKUs by the end of 2022.” 

Earlier this year Cosmos announced an LOI to acquire ZipDoctor Inc. from American International Holdings Corp (AMIH). AMIH will continue to manage all aspects of the day-to-day operations of ZipDoctor including product development, marketing, and operational support. ZipDoctor Inc., is a direct-to-consumer subscription-based telemedicine platform, that expects to provide its customers affordable, unlimited, 24/7 access to board certified physicians and licensed mental and behavioral health counselors and therapists. ZipDoctor’s online telemedicine platform will be available to customers across the United States and offers English and Spanish coverage with virtual visits taking place either via the phone or through a secured video chat platform. 

On October 17, 2022, Cosmos entered into a Securities Purchase Agreement with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a public offering, an aggregate of $7,500,000 of securities, consisting of (i) 62,500,000 shares of Common Stock, (ii) pre-funded Warrant in lieu of shares of Common Stock, and (iii) warrants to purchase 125,000,000 shares of Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”).  Under the terms of the Purchase Agreement, the Company agreed to sell one share of its Common Stock or a Pre-Funded Warrant and two Common Warrants for each share of Common Stock or Pre-Funded Warrant sold at a unit price of $0.12.  For each of 15,662,603 Pre-Funded Warrant sold in the Offering, the number of shares of Common Stock offered were decreased on a one-for-one basis. 

https://twitter.com/AirGoodman24/status/1591938222548189186

 For More on COSM Subscribe Right Now!

Currently trading at a $10 million market valuation COSM is the latest potential short squeeze at the top of speculators watch lists. With $35 million in current liabilities and an inability to collect on accounts receivables that currently stand at over $25 million COSM stock has lagged even as the Company reports its first ever net income on $13,208,504 in revenues for the 3 months ended June 30, 2022. The short position on COSM has grown to well over 5 million shares short and currently the entire public float is sold short. Now that the cat is out of the bag and the stock is surging northbound COSM short squeeze should be at the top of small cap speculators watch lists. We will be updating on COSM when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in COSM either long or short and we have not been compensated for this article.

Continue Reading

BioPharma

Vision Energy Inc., (OTCMKTS: VIHDD) Promo Continues as Phase 1 of Vision Energy’s Green Energy Terminal in Vlissingen Inks Major Engineering Deal

Published

on

Vision Energy Inc., (OTCMKTS: VIHDD) is making a powerful run up the charts up another 7% on Friday on well over $2 million in dollar volume. The Company put out big news on Thursday announcing it has partnered with Linde Engineering, to deliver preliminary Front-End Engineering and Design (FEED) services to its Green Energy Terminal in North Sea Port of Vlissingen, the Netherlands for Phase 1 of Vision Energy’s Green Energy Terminal via the Company’s subsidiary Evolution Terminals BV. Linde Engineering adds a lot of credibility to this deal; the Company is a global industrial gases and engineering company with 2021 sales of $31 billion. 

Speculators love the kind of run that VIHDD is making here, every single day it goes a little bit higher. Starting in the last few days of September Vision Energy stock has steadily been running northbound from around $4 pre-split to $32 pre-split or currently $16 per share after the 2 for 1 forward stock split on November 8. The ticker symbol will lose the extra D in 16 business days from now. Vision Energy has a history of explosive moves up the charts skyrocketing from $2.50 in December 2020, to highs of $50 per share in January 2021. That run however, ended very abruptly and the stock fell back to where it started. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Vision Energy Inc.,VisionH2 Announces Name Change and Forward Split (OTCMKTS: VIHD) is an integrated energy company developing assets and solutions for the commercial, industrial and transportation sectors. Leveraging its proven track-record in site and asset procurement, accelerating development and permitting processes, plant design, and grid integration to facilitate low-carbon energy production, supply and distribution. The Company pursues reliable offtake relationships and operating partnerships with energy industry participants and end users seeking carbon abatements across feedstock and fuels. Vision Energy is committed to providing low carbon energy solutions with the highest yield, and where possible, projects are designed to leverage existing gas and power infrastructure to integrate and facilitate import and or distribution of reduced-carbon energy to domestic and global supply chains. Vision Energy is a portfolio company of First Finance, a private equity investment group with offices in Zurich, London and Vancouver. 

Vision Energy’s 100% owned Vlissingen green hydrogen development project located in Vlissingen (Flushing) Netherlands is currently in its Phase 1 Development Plan designed for the construction of approximately 400,000 cubic meters (CBM) of renewable liquid bulk storage capacity comprising 150,000 CBM allocated to Green Ammonia, 180,000 CBM allocated to Renewable Methanol and 70,000 CBM allocated to Biofuels and Liquid Organic Hydrogen Carriers (LOHC). Phase 1 CAPEX is estimated at EUR €450 million, including jetty infrastructure.

Vision Energy Vlissingen is the Company’s launching project, and its focus is on the construction of a 25 MW green hydrogen plant in the Vlissingen Port area, in the province of Zeeland. 

Initial planning and pre-development work having been concluded, Vision Energy submitted the permit application to Vlissingen Municipality and Zeeland Province end of April. This hydrogen plant will produce H2 using electrolysis and will include storage, loading and distribution facilities for evacuating the H2. Initially the plant will produce up to 3,600 tonnes of green hydrogen annually, it is however capable of producing over double that quantity. Furthermore, the concept of the hydrogen plant allows for future expansion of up to at least 100 MW, potentially increasing H2 production to around 30.000 tonnes annually. 

The project site is strategically located on an industrial plot of 30.000m2 in the Vlissingen Oost industrial park. The site is accessible by road, rail and waterway to support the supply and distribution of green hydrogen to consumers in the region, as well as to neighboring industrial companies who are already planning on using green hydrogen to decarbonize their operations. The Vlissingen hydrogen plant also is located next to the Sloecentrale electricity generating plant creating potential synergies. 

Vision Energy’s 50% owned Terneuzen green hydrogen development project located in the North Sea Port of Terneuzen, Netherlands, in partnership with Virya Energy, is developing a 25 MW green hydrogen production facility with tube-trailer loading and integrated distribution facilities. This scalable platform allows the partnership to scale up production capacity at this Site to 75 MW.  At 25 MW the plant will produce up to 3.5 million kilograms of green hydrogen per year, and up to 10.5 million kilograms of H2 output at 75 MW. The Project Site is strategically located near existing high voltage power and gas infrastructure as well as large renewable power producing assets for the supply of green electrons and large industrial customers for future offtake of clean hydrogen. Less than 1,500 metres from the Project Site is the 150kV ground station of TenneT, the Dutch national high voltage grid operator, and less than 1,400 metres away is the connection point to the Yara-Dow-Zeeland Refinery Pipeline which may be repurposed for H2 transport to the Zeeland Refinery in future. Adjacent to the Project Site is the Ghent-Terneuzen Canal, providing water access to the major European Port of Ghent. VisionH2 and Virya plan to build the initial 25 MW electrolysis plant using proven, commercially available technology. Projected development costs for the initial phase of the project are estimated at €35 – €40 million. 

https://twitter.com/stockscan01/status/1590075102946803714

To Find out the inside Scoop on VIHDD Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

On November 10 Vison Energy through its wholly-owned subsidiary Evolution Terminals BV, has partnered with Linde Engineering, to deliver preliminary Front-End Engineering and Design (FEED) services to the project for Phase 1 of Vision Energy’s Green Energy Terminal. Scope includes design and engineering of 150,000 cubic meters (CBM) of Green Ammonia (NH3) storage, truck and barge loading facilities, ship loading and unloading facilities, and utilities, infrastructure and buildings, to accelerate engineering efforts for the Company’s pioneering Green Energy Terminal in North Sea Port of Vlissingen, the Netherlands. Engineering efforts under the agreement have commenced and are anticipated to conclude in April 2023 in support of the Company’s target to reach Final Investment Decision (FID) by Q3 2023. 

Vision Energy is in the advanced stages of planning for the construction and delivery of Northwestern Europe’s first import, storage and handling terminal designed exclusively for hydrogen carriers, renewable energy products and low-carbon fuels. The Company is scheduled to file all remaining environmental and construction permits by December 2022. Total capacity under Phase 1 is for up to 400,000 CBM including 150,000 CBM allocated to Green Ammonia, 180,000 CBM allocated to Renewable Methanol and 70,000 CBM allocated to Biofuels. Linde is a leading global industrial gases and engineering company with 2021 sales of $31 billion (€26 billion). We live our mission of making our world more productive every day by providing high-quality solutions, technologies and services which are making our customers more successful and helping to sustain and protect our planet. 

Vision Energy CEO Andrew Hromyk stated: “Our cooperation with Linde Engineering marks a critical milestone in our development, to deliver this world-class project with the vast global expertise Linde possesses. Our Green Energy Terminal Project will accelerate and advance the energy transition and facilitate Northwestern Europe’s ambition to achieve Net Zero through carbon-abatement and adoption of hydrogen as a core feedstock and fuel.” 
John van der Velden, Senior Vice President Global Sales & Technology at Linde Engineering said: “We are proud to work with Vision Energy on the sustainable development of this ammonia terminal, leveraging our extensive EPC expertise and clean energy technology to enable the green hydrogen economy.”  

 For More on Vison Energy Subscribe Right Now!

Currently trading at a $620 million market valuation Vision Energy is a fully reporting SEC filer OTCQB with $5.5 million in the treasury and is virtually debt free with no convertible debt on the books. The stock has been rocketing northbound over the past week as the Company has put out a number of press releases as things ramp up for its 100% owned Green Energy Hub development project in the North Sea Port of Vlissingen, the Netherlands. This is a massive project; Phase 1 CAPEX is estimated at EUR €450 million, including jetty infrastructure. However, Vision Energy is being promoted and currently the Company does not have the assets to justify this valuation and while the slow steady rise every single day is great, one day the stock could crash, and when it does it could drop very, very quickly. As we said in our last article the stock made a spectacular run back in January 2021 from $2.50 to $50 in a month and is embarking on another big run now which may end similar to the last move which went very high very quickly but dropped just as fast when the promotion ended. Vision Energy will be trading as VIHDD for the next 16 trading days, after which the Company will be assigned a new ticker symbol. We will continue to report on this situation as it unfolds and more information becomes available. We will be updating on VIHDD when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in VIHDD either long or short and we have not been compensated for this article.

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.